• News
  • SAN DIEGO
  • Medical

Amgen, Illumina team on personalized medicine test

Biotech drugmaker Amgen and Illumina, a maker of genetic testing equipment, said Wednesday they are developing a test that will identify patients who might be helped by Amgen's colon cancer drug Vectibix.

Vectibix is approved as a treatment for colorectal cancer that has spread and hasn't responded to chemotherapy. It's intended for patients who tend to have a less aggressive form of the cancer: the drug is not indicated for those with a genetic mutation that is associated with more aggressive cancers and lower survival rates. Amgen and Illumina want to develop a test that will determine whether patients have that mutation.

The companies said the test will run on Illumina's MiSeqDx sequencing system. Financial terms of their partnership weren't disclosed.

Shares of Amgen (Nasdaq: AMGN), based in Thousand Oaks, Calif., rose 79 cents to close at $118.51 Wednesday. Shares of San Diego-based Illumina (Nasdaq: ILMN) fell 39 cents to $121.12.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Illumina Inc.

Company Website

9885 Towne Centre Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ILMN
150.22
  -1.62  
- 1.07%
1,601,217,000
242.37
130.0

Insider Trade Data

Date Insider Shares Type Value
10/15/2015 Flatley, Jay T 10,000 Sell $1,500,000
10/15/2015 Flatley, Jay T 10,000 Exchange $279,700
10/15/2015 Flatley, Jay T 10,000 Sell $1,500,000
10/07/2015 Bradbury, Daniel M 1,700 Sell $247,878
10/07/2015 Bradbury, Daniel M 1,700 Exchange $75,667

Illumina Inc. Executive(s):

Jay Flatley

  • Chief Executive Officer, President

Similar Companies

NAICS - 334516 - Analytical Laboratory Instrument Manufacturing
Subscribe Today!